https://www.selleckchem.com/products/go-203.html
74, 95% confidence interval (CI) 20.48-58.93] and change in Hb from BL [roxadustat - placebo +1.692 (95% CI 1.52-1.86); both P 0.001]. Superiority of roxadustat was demonstrated for low-density lipoprotein cholesterol change from BL, and time to first use of rescue medication (both P 0.001). The incidences of treatment-emergent adverse events were comparable between groups (roxadustat 87.7%, placebo 86.7%). Roxadustat demonstrated superior efficacy versus placebo in terms of both Hb response rate and change in Hb from BL. The s
Like
Comment
Share
